DOCSLIB.ORG

Low Cost Malaria Detection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Low Cost Malaria Detection Low Cost Malaria Detection A Major Qualifying Project Report submitted to the faculty of WORCESTER POLYTECHNIC INSTITUTE in partial fulfillment of the requirements for the degree of Bachelor of Science Submitted By: _______________________ Benjamin Grondin __________________________ Benjamin Hassett _________________________ Taryn Loomis ___________________________ Professor Zoe Reidinger Ph.D., Advisor Department of Biomedical Engineering Table of Contents Table of Contents ....................................................................................................................... 1 Authorship Page ........................................................................................................................ 5 Abstract...................................................................................................................................... 6 Table of Figures ......................................................................................................................... 7 Table of Tables .......................................................................................................................... 8 Chapter 1: Introduction ............................................................................................................... 9 Chapter 2: Literature Review .....................................................................................................11 2.1 Malaria ............................................................................................................................11 2.1.1 History of Malaria ......................................................................................................11 2.1.2 Why is Malaria Still a Problem ...................................................................................11 2.2 Pathogenesis and Biology of Malarial Parasites in Humans.............................................12 2.2.1 Malarial Life Cycle .....................................................................................................12 2.2.2 Biology and Symptoms..............................................................................................13 2.2.3 Biomarkers ................................................................................................................14 2.3 Current Standards of Malaria Detection ...........................................................................17 2.3.1 Clinical Diagnosis ......................................................................................................17 2.3.2 Microscopy ................................................................................................................17 2.3.3 Rapid Diagnostics Tests ............................................................................................18 2.3.4 Treatment After Diagnosis .........................................................................................20 Chapter 3: Project Strategy .......................................................................................................21 3.1 Initial Client Statement .....................................................................................................21 3.2 Design Requirements: Technical .....................................................................................21 3.2.1 Objectives .................................................................................................................21 3.2.2 Functions ..................................................................................................................23 3.2.3 Constraints ................................................................................................................24 3.3 Design Requirements: Standards ....................................................................................24 3.4 Revised Client Statement ................................................................................................25 3.5 Management Approach ...................................................................................................25 3.5.1 General Project Phases ............................................................................................25 3.5.2 Financial Management ..............................................................................................26 Chapter 4: Design Process .......................................................................................................27 1 4.1 Needs Analysis and Functions .........................................................................................27 4.1.1 Needs Criteria ...........................................................................................................27 4.1.2 Functions and Specifications .....................................................................................27 4.2 Conceptual Designs, Design Concept Prototyping, Feasibility Studies ............................29 4.2.1 Liver Biopsy ..............................................................................................................29 4.2.2 Retinopathy ...............................................................................................................29 4.2.3 Ultrasound.................................................................................................................30 4.3 Alternative Designs ..........................................................................................................30 4.3.1 Rigidity ......................................................................................................................31 4.3.2 Volatile Organic Compounds .....................................................................................31 4.3.3 Oximetry ...................................................................................................................32 4.3.4 Polarization ...............................................................................................................33 4.3.5 Antigen Markers ........................................................................................................34 4.4 Final Design Selection .....................................................................................................34 4.4.1 Design Concept ........................................................................................................34 4.4.2 Preliminary Evaluations of Design Concepts .............................................................35 4.4.3 Final Design and Chamber ........................................................................................35 4.4.4 Identification of Red Blood Cells ................................................................................39 4.4.5 Magnet ......................................................................................................................40 4.4.6 Syringe Pump ...........................................................................................................40 Chapter 5: Final Design Verification ..........................................................................................44 5.1 Preliminary Chamber Design ...........................................................................................44 5.2 Preliminary Fluid Flow Testing .........................................................................................46 5.2.1 Initial Blood Flow .......................................................................................................46 5.3 Final Chamber Design .....................................................................................................47 5.4 Blood Identification ..........................................................................................................49 5.4.1 Luminol Testing .........................................................................................................49 5.5 Final Fluid Flow Testing ...................................................................................................52 5.5.1 Water Flow ................................................................................................................52 5.5.2 Blood Flow: Clotting ..................................................................................................52 5.5.3 Chamber Seal ...........................................................................................................53 5.5.4 Healthy Blood Flow ...................................................................................................54 2 5.5.5 Infected Blood Flow ...................................................................................................54 5.6 Sterilization ......................................................................................................................55 5.6.1 Adhesion ...................................................................................................................55 5.6.2 Sterility ......................................................................................................................56 Chapter 6: Discussion ...............................................................................................................57 6.1 Objectives ........................................................................................................................57 6.1.1 Accuracy ...................................................................................................................57 6.1.2 Cost ..........................................................................................................................58
Load more

Recommended publications
  • Meeting Report
    Meeting Report EXPERT CONSULTATION ON PLASMODIUM KNOWLESI MALARIA TO GUIDE MALARIA ELIMINATION STRATEGIES 1–2 March 2017 Kota Kinabalu, Malaysia Expert Consultation on Plasmodium Knowlesi Malaria to Guide Malaria Elimination Strategies 1–2 March 2017 Kota Kinabalu, Malaysia WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC RS/2017/GE/05/(MYS) English only MEETING REPORT EXPERT CONSULTATION ON PLASMODIUM KNOWLESI MALARIA TO GUIDE MALARIA ELIMINATION STRATEGIES Convened by: WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC Kota Kinabalu, Malaysia 1–2 March 2017 Not for sale Printed and distributed by: World Health Organization Regional Office for the Western Pacific Manila, Philippines September 2017 NOTE The views expressed in this report are those of the participants of the Expert Consultation on Plasmodium knowlesi Malaria to Guide Malaria Elimination Strategies and do not necessarily reflect the policies of the World Health Organization. This report has been prepared by the World Health Organization Regional Office for the Western Pacific for governments of Member States in the Region and for those who participated in the Expert Consultation on Plasmodium knowlesi Malaria to Guide Malaria Elimination Strategies, which was held in Kota Kinabalu, Malaysia from 1 to 2 March 2017. CONTENTS ABBREVIATIONS SUMMARY 1. INTRODUCTION ............................................................................................................................................. 1 2. PROCEEDINGS ...............................................................................................................................................
    [Show full text]
  • Manual for the Microscopical Diagnosis of Malaria in Man
    NATIONAL INSTITUTE OP HEALTH Bulletin No. 180 MANUAL FOR THE MICROSCOPICAL DIAGNOSIS OF MALARIA IN MAN Federal Security Agency U. S. PUBLIC HEALTH SERVICE Washington, D. C. FEDERAL SECURITY AGENCY U. S. PUBLIC HEALTH SERVICE National Institute of Health Bulletin No. 180 MANUAL FOR THE MICROSCOPICAL DIAGNOSIS OF MALARIA IN MAN By AIMEE WILCOX, Assistant Technologist U. S. Public Health Service From the Division of Infectious Diseases National Institute of Health UNITED STATES GOVERNMENT PRINTING OFFICE WASHINGTON : 1942 For sale by the Superintendent ofDocuments, Washington, D. C. - - - - - - Price 30 cents ORGANIZATION OF THE NATIONAL INSTITUTE OF HEALTH Thomas Parran, Surgeon General, United States Public Health Service Dyer, R. E, Director, National Institute of Health Division of Biologics Control.—Chief, Senior Surgeon M. Y. Yeldee. Division of Chemistry.—Chief, Professor C. S. Hudson. Division of Chemotherapy.—Chief, Surgeon W. H. Sebrell, Jr. Division of Industrial Hygiene.—Chief, Medical Director J. G. Townsend. Division of Infectious Diseases. —Chief, Senior Surgeon Charles Armstrong. Division of Pathology.—Chief, Senior Surgeon R. D. Lillie. Division of Public Health Methods. —Chief, G. St.J. Perrott. Division of Zoology.-—Chief, Professor W. H. Wright. National Cancer Institute. —Chief, Pharmacologist Director Carl Voegtlin. FOREWORD This manual begins with a description of the morphology and life history of the parasites of the different species of malaria, a descrip- tion which is clear and thorough and should be useful to both the beginner in the subject and to one who may wish a concise review. The author uses throughout the terminology recommended by the Sub-Committee of the Health Organization of the League of Nations.
    [Show full text]
  • WHO Guidelines for the Treatment of Malaria
    GTMcover-production.pdf 11.1.2006 7:10:05 GUIDELINES FOR THE TREATMENT O F M A L A R I A GUIDELINES FOR THE TREATMENT OF MALARIA Guidelines for the treatment of malaria Guidelines for the treatment of malaria WHO Library Cataloguing-in-Publication Data Guidelines for the treatment of malaria/World Health Organization. Running title: WHO guidelines for the treatment of malaria. 1. Malaria – drug therapy. 2. Malaria – diagnosis. 3. Antimalarials – administration and dosage. 4. Drug therapy, Combination. 5. Guidelines. I. Title. II. Title: WHO guidelines for the treatment of malaria. ISBN 92 4 154694 8 (NLM classification: WC 770) ISBN 978 92 4 154694 2 WHO/HTM/MAL/2006.1108 © World Health Organization, 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20, avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Laboratory Diagnosis of Malaria Infection – a Short Review of Methods
    Laboratory diagnosis of malaria infection – A short review of methods Kesinee Chotivanich1 Kamolrat Silamut2 Nicholas P J Day2,3 1Department of Clinical Tropical Medicine, Faculty of Tropical Medicine. Mahidol University. Bangkok. Thailand 2Wellcome Trust-Mahidol University-Oxford Tropical Medicine Programme, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand 3Center for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Churchill Hospital, University of Oxford, Oxford, United Kingdom. Abstract diagnosis. Microscopic diagnosis of malaria is performed by staining Malaria is one of the most important tropical infectious diseases. The thick and thin blood films on a glass slide to visualize the malaria incidence of malaria worldwide is estimated to be 300–500 million parasite (2). Briefly, the patient’s finger is cleaned with alcohol, allowed clinical cases each year with a mortality of between one and three to dry and then the side of the fingertip is pricked with a sharp sterile million people worldwide annually. The accurate and timely diagnosis lancet or needle and two drops of blood are placed on a glass slide. To of malaria infection is essential if severe complications and mortality prepare a thick blood film, a blood spot is stirred in a circular motion are to be reduced by early specific antimalarial treatment. This review with the corner of the slide, taking care not make the preparation details the methods for the laboratory diagnosis of malaria infection. too thick, and allowed to dry without fixative. As they are unfixed the red cells lyse when a water based stain is applied. A thin blood film is Keywords: malaria, diagnosis, microscopy, rapid prepared by immediately placing the smooth edge of a spreader slide in the drop of blood, adjusting the angle between slide and spreader This article has previously been published in the Australian Journal of to 45°, and then smearing the blood with a swift and steady sweep Medical Science 2006; 27 (1): 11-15 and is reprinted here with kind along the surface.
    [Show full text]
  • Treatment of Malaria: Guidelines for Clinicians
    TREATMENT GUIDELINES Treatment of Malaria (Guidelines For Clinicians) If you wish to share your clinical experience, please contact us at: [email protected] Treatment Table The Treatment Table is available in PDF format at www.cdc.gov/malaria/pdf/treatmenttable.pdf Reporting We encourage clinicians to report all cases of laboratory-confirmed malaria to help CDC's surveillance efforts. Refer to our information on the Malaria Case Surveillance Report Form (http://www.cdc.gov/malaria/report.html). Evaluation and Diagnosis Because malaria cases are seen relatively rarely in North America, misdiagnosis by clinicians and laboratorians has been a commonly documented problem in published reports. However, malaria may be a common illness in areas where it is transmitted and therefore the diagnosis of malaria should routinely be considered for any febrile person who has traveled to an area with known malaria transmission in the past several months preceding symptom onset. Symptoms of malaria are generally non-specific and most commonly consist of fever, malaise, weakness, gastrointestinal complaints (nausea, vomiting, diarrhea), neurologic complaints (dizziness, confusion, disorientation, coma), headache, back pain, myalgia, chills, and/or cough. The diagnosis of malaria should also be considered in any person with fever of unknown origin regardless of travel history. Patients suspected of having malaria infection should be urgently evaluated. Treatment for malaria should not be initiated until the diagnosis has been confirmed by laboratory investigations. "Presumptive treatment" without the benefit of laboratory confirmation should be reserved for extreme circumstances (strong clinical suspicion, severe disease, impossibility of obtaining prompt laboratory confirmation, usually by microscopy). Laboratory diagnosis of malaria can be made through microscopic examination of thick and thin blood smears.
    [Show full text]
  • WO 2016/193753 A2 8 December 2016 (08.12.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/193753 A2 8 December 2016 (08.12.2016) P O P C T (51) International Patent Classification: (74) Agent: BOULT WADE TENNANT; Verulam Gardens, A61B 90/00 (2016.01) 70 Gray's Inn Road, London WC1X 8BT (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/GB20 16/05 1649 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 3 June 2016 (03.06.2016) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/170,768 4 June 2015 (04.06.2015) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: ENDOMAGNETICS LTD. [GB/GB]; Jef freys Building, St John's Innovation Park, Cowley Road, (84) Designated States (unless otherwise indicated, for every Cambridge, Cambridgeshire CB4 0WS (GB).
    [Show full text]
  • Vaccines As a Preventive Modality for Malaria: a Review
    Vaccines as a Preventive Modality for Malaria: A Review Alka K. Singh, Vivek M. Ghate, Shaila A. Lewis Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India Abstract Malaria is one among the several parasitic infections that continue to claim lives despite the tremendous progress in the techniques for diagnosis, prevention, and treatment. Although the figures of malaria-ridden patients are decreasing in all the countries due to the collective efforts from all sectors of the society, the tropical countries are REVIEW ARTICLE REVIEW still facing severe setbacks in the implementation of the health measures due to the emergence of resistant strains and non-availability of appropriate medications at the required time. An efficient strategy would be to develop vaccines to prevent malaria from occurring than treating it. This review reflects the significant progress made in the field of vaccines and the challenges associated with it. A comprehensive summary is provided for the various diagnostic tests available for detecting malaria and the aspects of treatment related to infections during pregnancy. Key words: Diagnosis, malaria, parasite, pregnancy, vaccine INTRODUCTION to the population accounting for the death of one child (under the age of 5 years) every 2 min.[4] plague of the poor - malaria is a deadly disease caused by parasites.[1,2] In the The World Health Assembly has adopted a “Global Technical year 2016, the number of new cases Strategy for Malaria 2016–2030” in the year 2015, which A gives guidance to all the countries in the efforts they are of malaria was reported to touch 216 million, as a result of which the total number of deaths putting in for malaria eradication.
    [Show full text]
  • Analysis of Research and Development Priorities for Malaria – Working Paper
    Global Malaria Programme Analysis of research and development priorities for malaria – working paper In collaboration with the WHO Global Observatory on Health R&D Framework for a national insecticide resistance monitoring and management plan for malaria vectors Global Malaria Programme World Health Organization 20 Avenue Appia CH-1211 Geneva 27 Switzerland Prepared in collaboration with the Barcelona Institute for Global Health, the Malaria Eradication Scientific Alliance and WHO Global Malaria Programme August 2018 © World Health Organization 2018 All rights reserved. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. CONTENTS LIST OF FIGURES AND TABLES ................................................................................................................................................................. 3 ACKNOWLEDGMENTS ................................................................................................................................................................................... 4 ABBREVIATIONS ................................................................................................................................................................................................ 5 EXECUTIVE SUMMARY ................................................................................................................................................................................
    [Show full text]
  • Liquid Penetrant and Magnetic Particle Testing at Level 2
    XA0054311 Liquid Penetrant and Magnetic , 1 Particle Testing at Level 2 Manual for the Syllabi Contained in IAEA-TECDOC-628, ' "-ft "Training Guidelines in Non-destructive Testing Techniques" 3 1-16 •\ TRAINING COURSE SERIES TRAINING COURSE SERIES No. 11 Liquid Penetrant and Magnetic Particle Testing at Level 2 Manual for the Syllabi Contained in IAEA-TECDOC-628, "Training Guidelines in Non-destructive Testing Techniques" INTERNATIONAL ATOMIC ENERGY AGENCY, 2000 The originating Section of this publication in the IAEA was: Industrial Applications and Chemistry Section International Atomic Energy Agency Wagramer Strasse 5 P.O. Box 100 A-1400 Vienna, Austria LIQUID PENETRANT AND MAGNETIC PARTICLE TESTING AT LEVEL 2 IAEA, VIENNA, 2000 IAEA-TCS-11 © IAEA, 2000 Printed by the IAEA in Austria February 2000 FOREWORD The International Atomic Energy Agency (IAEA) has been active in the promotion of non- destructive testing (NDT) technology in the world for many decades. The prime reason for this interest has been the need for stringent standards for quality control for safe operation of industrial as well a nuclear installations. It has successfully executed a number of programmes and regional projects of which NDT was an important part. Through these programmes a large number of persons have been trained in the member states and a state of self sufficiency in this area of technology has been achieved in many of them. All along there has been a realization of the need to have well established training guidelines and related books in order, firstly, to guide the IAEA experts who were involved in this training programme and, secondly, to achieve some level of international uniformity and harmonization of training materials and consequent competence of personnel.
    [Show full text]
  • The President's Malaria Initiative Fourth Annual Report To
    The President’s Malaria Initiative Sustaining Momentum Against Malaria: Saving Lives in Africa Fourth Annual Report April 2010 The President’s Malaria Initiative Sustaining Momentum Against Malaria: Saving Lives in Africa Fourth Annual Report April 2010 Cover photo A child carries the long-lasting insecticide-treated net her family received during a net distribution campaign in her village in Ghana. To reduce the intolerable burden of malaria, the President’s Malaria Initiative targets those most vulnerable to the infection – children under the age of five and pregnant women. Credit Lisa Kramer/PMI ii Sustaining Momentum Against Malaria: Saving Lives in Africa www.pmi.gov TABLE OF CONTENTS Abbreviations and Acronyms . .v Executive Summary . .2 Chapter 1: Prevention – Insecticide-Treated Mosquito Nets . .11 Chapter 2: Prevention – Indoor Residual Spraying . .17 Chapter 3: Prevention – Malaria in Pregnancy . .23 Chapter 4: Case Management – Diagnosis and Treatment . .29 Chapter 5: Health Systems, Integration, and Country Capacity . .35 Chapter 6: Partnerships . .41 Chapter 7: Outcomes and Impact . .47 Chapter 8: U.S. Government Malaria Research . .53 Appendix 1: PMI Funding FY 2006–FY 2010 . .59 Appendix 2: PMI Activity Summary . .60 Appendix 3: PMI Country-Level Targets . .69 Acknowledgments . .70 Sustaining Momentum Against Malaria: Saving Lives in Africa www.pmi.gov iii iv Sustaining Momentum Against Malaria: Saving Lives in Africa www.pmi.gov ABBREVIATIONS AND ACRONYMS ACT Artemisinin-based combination therapy AL Artemether-lumefantrine
    [Show full text]
  • Tracking Number: DDTBMQ000044
    Drug Development Tool (DDT) Tracking number: DDTBMQ000044 Submission: Drug Development Tool Biomarker Qualification Proposal, received by Center for Drug Evaluation and Research (CDER) DDT name: Plasmodium falciparum 18S ribosomal (r)RNA/rDNA A type Context of use: The submitter proposed the following context of use: Detection of the P. falciparum 18S rRNA/rDNA is a safety (and efficacy) endpoint for initiating treatment before clinical malaria symptoms appear in subjects who have undergone P. falciparum sporozoite controlled human malaria infection (CHMI) in non-endemic regions. The biomarker can be tested for at ≥6 days post-CHMI in human whole blood. The P. falciparum 18S rRNA/rDNA biomarker must have been measured with one or more specific nucleic acid amplification-based methods. This biomarker is intended to replace the use of thick blood smear (TBS) microscopy for this endpoint. The context of use was modified during Biomarker Qualification Review Team discussions as follows: A monitoring biomarker to inform initiation of rescue treatment with an anti-malarial drug following controlled human malaria infection (CHMI) with P. falciparum sporozoites in healthy subjects from non-endemic areas enrolled in clinical studies for vaccine and drug development against P. falciparum. Submitter: Dr Sean C. Murphy, M.D., Ph.D. University of Washington Medical Center, Seattle, WA Digitally signed by Shukal Bala -S DN: c=US, o=U S. Government, ou=HHS, ou=FDA, ou=People, cn=Shukal Bala -S, Reviewer: Shukal Bala, Ph.D. Shukal Bala -S 0.9.2342.19200300.100.1.1=1300068480 Microbiologist Date: 2018.05.10 14:34 51 -04'00' Division of Anti-Infective Products (DAIP), Office of Antimicrobial Products (OAP), CDER Through: Sumati Nambiar, M.D., M.P.H.
    [Show full text]
  • Cobalt – Essential to High Performance Magnetics
    COBALT Essential to High Performance Magnetics Robert Baylis Steve Constantinides Manager – Industrial Minerals Research Director of Technology Roskill Information Services Ltd. Arnold Magnetic Technologies Corp. London, UK Rochester, NY USA Our World Touches Your World Every Day… © Arnold Magnetic Technologies 1 • Magnetic materials range from soft (not retaining its own magnetic field) to hard (retaining a field in the absence of external forces). • Cobalt, as one of the three naturally ferromagnetic elements, has played a crucial role in the development of magnetic materials • And remains, today, essential to some of the highest performing materials – both soft and hard. Agenda • Quick review of basics • Soft magnetic materials • Semi-Hard magnetic materials • Permanent Magnets • Price Issues • New Material R&D Our World Touches Your World Every Day… © Arnold Magnetic Technologies 2 • Let’s begin with a brief explanation of what is meant by soft, semi-hard and hard when speaking of magnetic characteristics. Key Characteristics of Magnetic Materials Units Symbol Name CGS, SI What it means Ms, Js Saturation Magnetization Gauss, Tesla Maximum induced magnetic contribution from the magnet Br Residual Induction Gauss, Tesla Net external field remaining due to the magnet after externally applied fields have been removed 3 (BH)max Maximum Energy Product MGOe, kJ/m Maximum product of B and H along the Normal curve HcB (Normal) Coercivity Value of H on the hysteresis loop where B = 0 HcJ Intrinsic Coercivity Value of H on the hysteresis loop where B-H = 0 μinit Initial Permeability (none) Slope of the hysteresis loop as H is raised from 0 to a small positive value μmax Maximum Permeability (none) Maximum slope of a line drawn from the origin and tangent to the (Normal) hysteresis curve in the first quadrant ρ Resistivity μOhm•cm Resistance to flow of electric current; inverse of conductivity Our World Touches Your World Every Day… © Arnold Magnetic Technologies 3 • These are most of the important characteristics that magnetic materials exhibit.
    [Show full text]